accountOasmia Pharmaceutical AB rose the most on record after it signed a license and distribution agreement with Abbott Laboratories for two canine cancer drug candidates, “significantly” expanding a 2009 deal.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Oasmia Soars on Global Dog Cancer Deal With Abbott Laboratories
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account